Cells expressing IG6 mRNA were detected by in situ hybridization in normal pituitaries. In normal untreated rat pituitary the expression was very low. Within hours after IP administration of liposaccharide, IG6 mRNA accumulated in the anterior lobe of the pituitary. Production of IC6 was monitored after dissociation and culture of pituitary cells. High levels (8000 pglml) were recovered after 72 hr in culture. In normal human pituitaries, less than 1% of cells expressed IG6 mRNA or IG6 receptor mRNA ( U -R "A).
Introduction
Data are accumulating that support the existence of a neuroimmunoendocrine network (1,2). Various hormones may influence lymphocyte function (1) . Conversely, secretory products of macrophages and lymphocytes modulate endocrine function (3) (4) (5) (6) (7) (8) . Interleukin-6 (IL-6), for example, is produced by the anterior pituitary (9) (10) (11) . IL-6 is a pleiotropic cytokine acting not only on lymphocytes but also on liver and brain. The effects of IL6 on pituitary cell secretion remain a matter of debate (9) (10) (11) . We are interested in identifying growth factors that may contribute to development or progression of pituitary adenomas. We therefore decided to look for expression of IL6 in pituitary tumors. We report here the presence of IL-6 mRNA and IL-6-R mRNA in GHand ACTH-secreting adenomas and also in normal pituitaries. When IL6 was expressed, mRNA coding for the IL6 receptor (IL-6-R) was also expressed in the same area. Finally, the presence of IL-6 mRNA was documented in normal rat pituitary and IL-6 was measured in culture medium from dissociated rat pituitary cells. 
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Materials and Methods
Cell Dissociation and Purification of Rat Pituitary Cells. Dissociation and purification of anterior pituitary cells were performed as previously described (12). Briefly, for each experiment cells were prepared from anterior pituitaries of 20 nulliparous female Wistar rats (Proefdierencentrum; Leuven, Belgium) at random cycle stages. The tissues were minced and dissociated enzymatically and mechanically. The cell suspension (2.5-3 x IO6 cells per pituitary) was filtered through nylon gauze, washed, and centrifuged. Cells were layered on top of a discontinuous Percoll gradient (Pharmacia; Uppsala, Sweden) (densities 1.045, 1.065, 1.080, and 1.090) and centrifuged for 20 min at 400 x g in a swing-out rotor at room temperature (RT). Three cell layers were obtained by collecting cells at the interphases of the solutions of the mentioned densities: Layer 1 corresponds to interphase 1.045-1.065 and was enriched in PRL cells to 85%; Layer 2 at interphase 1.065-1.080 was a mixed GH and PRL cell layer. Layer 3 was recovered at interface 1.080-1.090 and was enriched in GH cells to 93%. For each experiment, cells in each fraction were characterized by immunocytochemistry (see also 12).
Rat Pituitary Cell Culture. Freshly dissociated cells (total cell suspension and cells from Layers 1 and 2) were seeded on tissue culture coverslips (15 mm) (Thermanox; Miles Laboratories, Naperville, IL) in 24-well dishes (Falcon; Oxnard, CA). They were plated at a density of 5 x IO* cells/wcil in 1 ml culture medium (DMEM supplemented with 0.012 M NaHC03, 0.015 M Hepes, 0.015 M TES (2-{(tris-(hydroxymethyl)-methyl]amino) ethanesulfonic acid) (Calbiochem; San Diego, CA), and 10% newborn calf serum (Gibco; Grand Island, NY), 35 pg/ml penicillin, and 50 pg/ml streptomycin (Sigma; St. Louis, MO) adjusted to pH 7.3 and maintained at 37'C 67 YEJXENERS, YERGAM, TROUILLAS, DHAENS, HOOGHE, HOOGHE-PETERS in 5% CO2 humidified atmosphere. Cells were used either directly after dissociation or after 3 days in culture.
Production of IL6 by Rat Pituitary Cells. Cultures were treated with liposaccharide from E. coli (LPS) (Difco; Detroit, MI) 1 pg/ml or vehicle (PBS) only, either immediately after plating or after 3 days of culture. Twentyfour hours later medium was collected, centrifuged, and the supernatant was frozen until assay For bioassay, the IL6-dependent 7TD1 hybridoma (kindly provided, together with reference recombinant mouse IL-6, by Dr J. Van Snick, Ludwig Institute for Cancer Research, Brussels, Belgium) was used (13) . This assay for mouse IL6 also allows quantification of rat IL6 levels U. Van Snick, personal communication).
Cell and Tissue Preparation. Pituitary and spleen were obtained from female Wistar rats, treated or not with LPS. Treatment consisted of a single injection of 25 pg LPS in 0.5 ml PBS; control animals received the same volume of buffer. After 6 hr, animals were sacrificed and pituitary and spleen processed for subsequent in situ hybridization. Tissues were rinsed in PBS for removal of blood, frozen in isopentane or dry ice, and stored at -70°C.
Normal human pituitary and spleen were obtained within 4 hr post mortem. Human tonsils were surgically removed. The human pituitary adenomas were removed by the transsphenoidal surgical approach. Of five ACTH-secreting macroadenomas, four patients presented with clinical Cushing's disease and biochemical evidence of ACTH and cortisol hypersecretion. One adenoma was not associated with Cushing's disease or any disturbance of dynamic pituitary function tests. The diagnosis of silent ACTH-producing tumor was made after immunocytochemical analysis. Six microprolactinomas were from young adult women who presented with hyperprolactinemia and had not been treated with bromocryptine. Of six GH-secreting adenomas, all patients presented with acromegaly except for one who had amenorrhea and galactorrhea. Some of the tumors expressed a plurihormonal immunohistochemical pattern, but GH was the predominant hormone. There were three GH-and PRLproducing adenomas, one adenoma producing GH and a-subunits, and two pure GH-secreting adenomas. Six nonfunctioning pituitary adenomas were evidenced by absence of hypersecretion of hormones. Immunohistochemical staining with hPRL. hGH, hPLH, hPFSH, hmSH, TSH, and a-subunits was also negative. Of two gonadotropinomas, one adenoma stained positively for PLH, PFSH, and a-subunits. The other stained positive for PFSH and a-subunits only. However, no clinical evidence was found for gonadotrophin hypersecretion.
Fragments of tissues were processed immediately as described for in situ hybridization (14) . For ISH, 5-7 -pm thick sections were cut with a cryostat equilibrated at -15°C and allowed to dry on poly-L-lysine (100 pglm1)treated glass slides. Freshly dissociated cells were also prepared for ISH as described (12).
In Situ Hybridization. Rat tissues and cells were hybridized with DNA complementary to the mouse (m) IL6 mRNA, labeled by random priming with 31S to a specific activity of 5 x 10' cpm/pg cDNA. This probe was kindly provided by Dr J. Van Snick.
The DNA complementary to the hIL6-R and hIL6 was obtained from Dr J. Content (Institut Pasteur du Brabant, Brussels, Belgium) and Dr T. Kishimoto (Institute of Molecular and Cellular Biology, Osaka, Japan), respectively, and was used for human tissue hybridization. Sections 5-7pm thick were cut with a cryostat at -1S'C and dried onto poly-L-lysinetreated slides (100 pglml). Preparations (cells and sections) of rat and human origin were fixed in paraformaldehyde 4% in PBS containing 5 mM MgC12 and 10 mM vanadylribonucleoside (VRC) (Bethesda Research Laboratory; Bethesda, MD) for 10 min at RT. After washing, slides were treated with 0.5% Triton X-100 in PBS containing 10 mM VRC, washed again, and dehydrated in graded ethanol. Slides were stored in 70% ethanol before hybridization. ISH was performed as described previously (14.15) . Controls included (a) competition with cold probe, (b) hybridization with irrelevant molecular probes such as cDNA insulin and cDNA albumin, and (c) pre-treatment of sections with RNAse. Controls were negative. Slides were air-dried and immersed in Ilford K2 emulsion diluted with the same volume of 0.6 M ammonium acetate, pH 7, at 42'C, placed for 5 min on a metal plate pre-equilibrated to 4'C, and air-dried at RT for 1-2 hr in the dark. After 2-6 weeks of exposure, slides were developed in Kodak D19 developer for 4 min and fixed in 30% sodium thiosulfate.
Immunocytochemistry for Pituitary Adenomas. For diagnostic procedures, paraffin-embedded fragments of adenomas were cut at 5-6 pm and stained for pituitary hormones by the avidin-biotin-peroxidase complex (ABC) method as described (16) . Frozen sections (17) were used for all other studies. For detection of IL6, sections were pre-treated with proteinase K (Sigma) 40 pg/ml for 10 min at 37°C (18) . The following primary antibodies were used. Mouse anti-human IL6 monoclonal antibodies (MAb) 8801 and 8812 were produced in ascites form in nude mice. 
Results
In Situ Hybridization of Rat Pituitary Sections or Cells
When sections of normal rat pituitaries were hybridized to probes complementary to mIL-6 mRNA, the distribution of grains was predominantly visualized over the endocrine cells of the anterior lobe. A few scattered cells of the posterior and intermediate lobes were positive but significantly less labeled than the cells in the anterior lobe ( Figure la) . The silver grain count increased after treatment of the rat with LPS ( Figure Ib) . In dissociated rat anterior pituitary cells from animals treated with LPS in vivo, 30% of cells were positive for mIL-6 mRNA (not shown). Several controls were included to assess the specificity of the in situ hybridization. Sections of rat spleen hybridized with the mIL-6 cDNA probe under identical conditions as the pituitary tissue also showed significantly higher mIL6 mRNA expression after injection of LPS. Positive cells were identified in the red pulp (Figures IC and Id) .
Production of ILG by Normal' Rat Pituitary Cells in Culture
Twenty-four hours after plating, low levels of IL-6 were measured in control and LPS-treated cultures ( 5 x lo4 cells plated in 1 ml), separate experiments. IL-6 was hardly detected even after stimulation with LPS in Layers 1 (PRLproducing cells mainly) and 2 (mixed population of PRL-and GH-secreting cells), 100 pglml in Layer 1 and <20 pglml in Layer 2 after 3 days in culture.
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and 7200 pglml, respectively. Similar data were obtained in two Spleen, Tonsil.., and Adenomas Expression of hIL-6 mRNA and the hIL-6-R mRNA was analyzed by in situ hybridization in normal human pituitaries obtained post mortem. Only rare scattered cells (<1./0) expressed the mRNA for IL-6 and IL-6-R ( Figure 2 ). We also analyzed the expression of hIL6 and its receptor in pituitary adenomas. In contrast to normal human pituitary tissues, all five ACTH-secreting adenomas showed 2-5% of cells expressing hIL-6 mRNA ( Table 1 ). These cells were located at the periphery of the tumor or in close apposition to blood vessels. In situ hybridization for one of the ACTH-secreting tumors (No. 3) is illustrated in Figure 3 . Three out of six GH-secreting adenomas bound both the hIL-6-R and the hIL-6 mRNA probes (Nos. 1, 4, and 5 ) . In one tumor (No. 6). a mixed GH-PRLproducing adenoma, up to 20% of cells were positive for hIL-6 mRNA (Figure 4a) only; no hIL-6-R message was detected. In the GH-PRL-expressing adenoma No. 5 (Figure 4b ). 30% of cells were clearly positive for hIL-6-R mRNA, although hIL-6 mRNA was present in only 5% of the cells. All prolactinomas. gonadotropinomas, and non-secreting tumors were negative for hIL-6 and hIL-6-R gene expression by in situ hybridization. Human spleen and tonsils served as positive controls in these experiments. Human spleen showed a pattern of cells expressing hIL6 mRNA comparable to that of rat spleen. IL-6-positive cells were also consistently demonstrated in surgically removed tonsils (20) .
Presence of IL-6 in Human Adenomas
With MAb to hIL-6. IL6 was demonstrated in a selected group of tumors positive for IL-6 mRNA (Figure 5 ) . Surprisingly, staining was observed only when sections were pre-treated with proteinase K. although this treatment was not required to visualize IL6 in spleen. IL6 was expressed at the boundary between the endocrine and the inflammatory areas of the tumors. The endocrine area of the tumors was stained with an anti-N-CAM (CD 56 MAb). which also stains human natural killer cells (Figure 7 ) (21) . Most infiltrating cells were stained with an anti-macrophage (Mac-3) MAb (Figures 6 and 7 ) . Double labeling for IL6 and surface markers was impossible because of the requirement for proteinase K treatment before visualization of IL-6 and the lack of resistance of surface markers to proteinase K.
Discussion
IL-6 is a cytokine produced by endothelial cells, fibroblasts, monocytes, and macrophages (22) . We document here the local expression of mIL-6 mRNA in situ and in dispersed cells of the anterior rat hypophysis by in situ hybridization. Few cells (about 1%) expressed IL6 mRNA in untreated rats. Treatment with LPS 6 hr before autopsy, however, dramatically increased the proportion of cells that expressed IL-6. We also confirmed earlier work demonstrating IL-6 secretion by pituitary cells in vitro @,IO), and measured IL-6 secretion in vitro after cell separation on a Percoll gradient. PRLenriched and mixed GH-PRL fractions produced less IL-6 per lo4 cells than unseparated cells, suggesting that IL-6 is also produced by cells that were lost during separation (about 25 "0) or by fraction .-_---- 3 (almost pure GH representing, however, a small fraction of GH cells in the pituitary, not tested). Alternatively, optimal production may require the interaction of cell types that do not co-purify on the Percoll gradient. Our data are in agreement with the conclusions of Spangelo et al. (9) that IL6-producing cells are separate from the PRL or GH-producing cell fractions. They are also compatible with the proposal by Vankelecom et al. (10) that folliculostellate cells make IL6. In LPS-treated cultures, we estimated that 30% of the cells expressed IL6 mRNA, and this implies that some endocrine cells become positive. Alternatively, LPS might induce proliferation of the IL6-producing cell type.
The physiological significance of IL6 production in the normal Dituitary remains controversial. Several authors have reported that IL6 affects GH or PRL release (9,lO) . However, we were unable to c o n f i i those fmdings (unpublished observations). Relevant to this point is our in situ study of IL6-R in normal human pituitary. Very fm, if any, endocrine cells expressed detectable levels of ILGR "A.
In normal human pituitary, only rare scattered cells (<I%) were positive for hIL6 "A.
It cannot be ruled out that under certain conditions (e.g., autoimmune disease or after aspxific uiggers) lymphokine level may be enhanced in the pituitary, as observed in the nervous system (17,22-24, and in rat pituitary stimulated with LPS. studied expressed both IL6 and IL6-R messengers. Ofthe six GHsccfeting adenomas, three e x p d IL6 mRNA and IL6-R m R N k a single mixed GH-PRLsecreting tumor contained the mRNA for IL6 and did not express IL6-R " A. In addition, all prolactinomas, non-secretory adenomas, and gonadotropinomas studied were negative for both messengers. The relationship betwcea elevated expression of IL6 and IL6-R mRNA suggests that IL6 contributes to the pathogenesis of ACTH-and GH-secming adenomas. It is interming to note that hepatoma cells treated with dexamethasone expressed more IL6-R than control cells (25) . Since hyperconicism was pment in four out of five ACTH-producing adenomas in the pment study, it is tempting to speculate that corticoids favor expression ofJL6-R and. as a consequence, the cellu-lar response to IL6. Recently, another group has obtained evidence for IL6 production by cultured human pituitary adenoma. Seven tumors out of 10 secreted IL6 (26) .
The cells producing E-6 are situated at the junction betwcen adenomacells and fibrous infiitmtiag tissue and also around blood vrs~k. The adenoma cells were stained with anti-CD56IN-CAM MAb (which stains neuroectodermal cells in addition to NK cells), It was impossible to unambiguously locate IL6 production in the endocrine or the infiitmting tissue. Double labeling experiments arc not feasible for surface mvkcrs that do not resist proteolytic treatment. Indeed. IL6 could be visualized in the pituitary only after treatment with proteinase K. Although such a treatment is and the bulk O f infiitmthg cells WTR stained With mti-Mz3 MAb. often required to unmask hidden epitopes (18), this was somewhat surprising, since such treatment was not required for spleen sections included in the same experiment.
Although it cannot be excluded that adenoma cells express IL6, we speculate that cells of the monocyte-macrophage series infdtrating the tumor produce IL6. Double-labeling experiments with nonradioactive molecular probes for both IL-6 and differentiation markers should clardy this area.
The target cells for IL6 in normal pituitary and adenomas are not known. A few cells expressed IL6-R mRNA in normal pituitary and higher values were found in some adenomas. We could not identify the cell type expressing IL6-R, which was localized at the boundary between adenoma and reactive tissues. Ohmichi et al. (27) recently reported expression of IL-6-R in the anterior pituitary glands of rat and human. In a double-labeling experiment, they observed co-localization of IL6-R and LH immunoreactivities in the pituitary gland of a 21-week human fetus. The presence of both IL-6 and IL6-R mRNA in the same tissues suggests a possible role for IL6 in the pathogenesis of ACTH-and GHsecreting adenomas. We indeed know that high numbers of IL6-R are found on human multiple myeloma cells (28) , where IL6 may thus function as a growth tumor factor in vitro (29, 30) . Moreover, these myeloma cells produce IL6, and antibodies against IL6 inhibit the growth of these tumors, suggesting an autocrine positive loop (28) . Autocrine positive loops have also been proposed for the astrocytoma cell line U337 and the myeloid cell line HL.60, since both express IL6 and IL-6-R (31) . Finally, the transfection of IL-6 cDNA in plasmocytomas increases tumorigenesis of these cells by about 100-fold over the IL6-dependent parental cells (25) .
The IP injection of IL6 results in increased levels of ACTH (32) . %ken together with the inability to evoke the release of ACTH from dispersed rat pituitary cells (25) , these data suggest a central action for IL6. Receptors for IL6 are expressed in the central nervous system (17) and IL6 is locally produced under normal and pathological conditions in the brain (17, 23, 24) . It would be interesting to check whether patients with ACTH-producing adenomas have increased IL6 serum levels. Even if IL-6 does not stimulate ACTH release, it may act as a growth or differentiation factor for ACTH cells.
It has also been proposed that IL6 has angiogenic activity (31) . This has not been tested in the pituitary. In our series of adenomas there was no correlation between the expression of IL6 (as seen by ISH or ICC) and vascularization. Clearly, however, cellular levels of mRNA or protein do not adequately reflect tissue levels of the secreted factor.
In conclusion, we demonstrate here the presence of IL6 and IL6-R mRNAs in both normal rat and normal human pituitary. Their expression was dramatically increased in the rat after LPS treatment in vivo and in certain human adenomas compared with normal pituitaries. IL6 may act as an autocrine or paracrine growth factor in ACTH and in some GH adenomas. Alternatively, the local production of IL6 may be only a secondary response to pituitary dysfunction.
